Catalyst Wire Dossier Catalyst Wire Dossier

Ivosidenib (Tibsovo)

ivosidenib · Agios Pharmaceuticals
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for Ivosidenib (Tibsovo), covering 2024-10-02 to 2026-01-09. Get the full timeline:

Most recent: Clinical Trial Update: Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation [Phase 1, Phase 2]

See pricing